technology

press releases

Date Title and Summary Additional Formats
Toggle Summary - 12-Month Data Presented at American Academy of Neurology (AAN) Annual Meeting Demonstrated Eptinezumab Further Reduced Migraine Risk Following Third and Fourth Quarterly Infusions - - Biologics License Application (BLA) Submission Expected in Q1 2019 - - Key Clinical Data Milestones, CMC Studies View HTML
Toggle Summary BOTHELL, Wash. , May 07, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Paul B. View HTML
Toggle Summary BOTHELL, Wash. , April 30, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its first quarter 2018 financial and operating results View HTML
Toggle Summary BOTHELL, Wash. , April 26, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) (“Alder” or the “Company”), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that its Board of Directors has unanimously View HTML
Toggle Summary Patients with a 75% or greater response experienced an eight-fold increase in migraine-free days and more meaningful improvements in bodily pain and physical function BOTHELL, Wash. , April 25, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company View HTML
Toggle Summary - Data presented at AAN Annual Meeting demonstrate eptinezumab further reduces migraine risk following the third and fourth quarterly infusions - More than 50% of patients achieved a 75% reduction or greater of migraine days BOTHELL, Wash. , April 24, 2018 (GLOBE NEWSWIRE) -- Alder View HTML
Toggle Summary BOTHELL, Wash. , April 23, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc. , (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Eric Carter , Ph.D., M.D., has been named Interim Chief Medical View HTML
Toggle Summary PROMISE 2 Phase 3 study selected for Emerging Science clinical trials plenary presentation session on April 24, 2018 BOTHELL, Wash. , April 18, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for View HTML
Toggle Summary Continues to Build Executive Team and Position Company for Next Stage of Growth and Development BOTHELL, Wash. , April 16, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) (“Alder” or the “Company”), a biopharmaceutical company focused on developing novel therapeutic antibodies View HTML
Toggle Summary BOTHELL, Wash. , March 20, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Paul B. Cleveland , a member of the Company’s Board of Directors, has View HTML